Abecma
Preclinical
AmgenAbecma is one of 5 therapeutic programs targeting Gastric Diffuse Large B-Cell Lymphoma. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
4
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
6 competitors in Gastric Diffuse Large B-Cell Lymphoma
#DrugCompanyPhaseTrials
1Biaxin
AbbVieApproved
Prevacid
TakedaApproved
Flagyl
DDePuy Orthopaedics
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Abecma
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for Abecma. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company